AlphAIAlphAI — Financial news for AI agents
tradingview.comNOV 31 min read$CLVT

Clarivate 3Q 2026: Revenue $481.6M, Net income ($80.8M), EPS ($0.13) — 10-Q Summary

Clarivate reported Q3 2026 revenue of $481.6M, down 9.2% YoY, and a net loss of $80.8M, or $0.13 per share, compared to a loss of $28.3M a year earlier. Recurring revenue rose 0.7%, while transactional revenue fell 57.9%. The company completed the sale of its Life Sciences & Healthcare segment.

Original reporting
tradingview.com
Published Nov 3, 2026, 1:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 1:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Clarivate 3Q 2026: Revenue $481.6M, Net income ($80.8M), EPS ($0.13) — 10-Q Summary — source image
Source · tradingview.com
Decision brief

The 30-second read

$CLVTBearishMed
01

Why it matters

The earnings miss is likely to depress the stock in the short term, though the stable renewal rate and recurring revenue growth provide a floor.

02

Market read

Primary earnings release for a mid‑cap analytics firm; relevant for traders with exposure to CLVT or the broader information services sector.

03

What to watch

The sale of the Life Sciences & Healthcare segment may improve future profitability.

Relevance 7/10Novelty 8/10Timing: post-market release

Background

Clarivate's Q3 2026 filing includes a revenue decline, larger net loss, and the recent divestiture of its Life Sciences & Healthcare segment.

Company-level read

Ticker impact

$CLVTBearishHigh confidence
Context

Clarivate posted Q3 2026 results with revenue down 9.2% and a net loss of $80.8M, marking a material earnings miss.

Expected impact

downward pressure as investors price in weaker revenue and larger loss

Evidence & confidence

The company reported a 9.2% revenue decline and a 185% increase in net loss versus the prior year, which typically leads to a negative market reaction.

Market effects

Sector

Signals potential softness in the analytics and information services sector.

Regional

U.S. listed analytics firms may see modest pullback.

Global

Limited to investors tracking mid‑cap earnings.

Counterpoint

What could challenge this read

If the market overreacts, the stock could rebound on the stable renewal rate and recurring revenue growth.

Key entities

  • Company
    Clarivate PLC

    Provider of analytics and information services, ticker CLVT.

Read at source← All news

StoryClarivate reports Q3 loss as continuing revenue falls after LS&H divestiture

Also covered by

5 outlets

Related articles

NOV 3
$CLVTHighAI 8/10

Clarivate Reports Third Quarter 2026 Results, Delivering Clear Path to Value Creation

CLARIVATE PLC (CLVT) filed an SEC Form 8-K — Results of Operations and Financial Condition. 1 Clarivate Reports Third Quarter 2026 Results, Delivering Clear Path to Value Creation — Improved recurring organic revenue growth driven by portfolio transformation and AI-led innovation — — Updates 2026 financial outlook following the divestiture of Life Sciences & Healthcare

SEC EDGAR 8-K3 min
NOV 3
$CLVTMed

Why is Clarivate stock sliding today?

Clarivate (CLVT) stock fell 5.4% in pre-market trading after Q3 2026 results beat EPS estimates ($0.21 vs. $0.18) but missed revenue forecasts by 16.7% ($481.6M vs. $566.77M), down 9.2% YoY. Full-year revenue guidance ($1.96B-$1.98B) also fell short of consensus ($2.20B). The miss was exacerbated by portfolio disposals and cautious forward outlook.

investing.com2 min
NOV 3
$CLVTHighAI 8/10

Clarivate shares fall 6% on revenue miss despite earnings beat

Clarivate (CLVT) reported Q3 earnings of $0.21 per share, beating estimates, but revenue of $481.6M missed expectations. Shares fell 6.63% premarket. Q4 guidance was mixed, with EPS matching estimates but revenue below. The company expects fiscal 2026 revenue of $1.97B, below consensus. Organic revenue grew 0.4% YoY, and adjusted EBITDA declined 1.8%.

investing.com2 min